Abstract
The aim of the current study was to evaluate the effectiveness of a long-term treatment with sodium valproate in 19 patients with Cushing’s disease. Before therapy beginning, the patients were subjected to acute test with 600 mg sodium valproate. Then, they were subjected to a 3-month therapy with sodium valproate at the dose of 600 mg/day before surgery (presurgical study). The 7 patients not surgically cured were subjected again to a 3-month therapy with sodium valproate at the dose of 600 mg/day after surgery (postsurgical study). Circulating ACTH and cortisol and urinary free cortisol levels were evaluated before and monthly after the beginning of the therapy. A decrease of plasma ACTH and serum cortisol levels greater than 50% of baseline was considered as positive response to acute test whereas the normalization of plasma ACTH, serum cortisol and urinary free cortisol levels and the clinical remission were considered as positive response to the long-term treatment. At acute test, 8 patients were considered responders and 11 patients non-responders. In no patient plasma ACTH, serum cortisol and urinary free cortisol were normalized during the long-term treatment. Urinary free cortisol levels significantly decreased (483.2±33.8 vs 699.4±67.0 ug/24 h), whereas plasma ACTH (302.8±17.7 vs 183.3±25.0 ng/l) and serum cortisol (466.5±23.2 vs 356.7±19.6 µg/l) significantly increased during sodium valproate administration in the 19 patients enrolled in the presurgical study. Plasma ACTH (247.7±22.3 vs 168.6±15.0 ng/l), serum cortisol (387.4±35.8 vs 282.0±16.0 µg/l) and urinary free cortisol (370.9±70.6 vs 261.3±37.8 µg/24 h) levels significantly increased in the 7 patients enrolled in the postsurgical study. No patient had clinical remission of Cushing’s disease. In conclusion, the current study showed that long-term therapy with sodium valproate is not useful in the therapeutic management of Cushing’s disease neither as alternative nor as adjunctive therapy to surgery.
Similar content being viewed by others
References
Ambrosi B., Faglia G., and the Multicenter Pituitary Study Group, Lombardia Region. Epidemiology of pituitary tumors. In: Faglia G., Beck-Peccoz P., Ambrosi B., Travaglini P., Spada A. (Eds.), Pituitary Adenomas. New Trends in Basic and Clinical Research. Excerpa Medica, Amsterdam, 1991, p. 159.
Etxabe J., Vázquez J.A. Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin. Endocrinol. (Oxf.) 40: 479, 1994.
Melby J.C. Therapy of Cushing’s disease: a consensus for pituitary microsurgery. Ann. Intern. Med. 109: 445, 1988.
Burch W. A survey of results with transsphenoidal surgery in Cushing’s disease. N. Engl. J. Med. 308: 103, 1983.
Tagliaferri M., Bersetti M.E., Loli P. Transsphenoidal microsurgery for Cushing’s disease. Acta Endocrinol. (Copenh.) 113: 5, 1986.
Mampalam T.J., Tyrell J.B., Wilson C.B. Transsphenoidal microsurgery for Cushing’s disease. Ann. Intern. Med. 109: 487, 1988.
Bochicchio D., Losa M., Buchfelder M., and the European Cushing’s Disease Survey Study Group. Factors influencing the immediate and late outcome of Cushing’s disease treated by transsphenoidal surgery: a retrospective study by the European Cushing’s Disease Study Group. J. Clin. Endocrinol. Metab. 80: 3114, 1995.
Welbourne R.B. Survival and causes of death after adrenalectomy in Cushing’s disease. Surgery 97: 16, 1985.
Littley M.D., Shalet S.M., Beardwell C.G., Ahmed S.R., Sutton M.L. Long-term follow-up of low-dose external pituitary irradiation for Cushing’s disease. Clin. Endocrinol. (Oxf.) 33: 445, 1990.
Degerblad M., Rahn T., Bergstrand G., Thoren M. Long-term results of stereotactic radiosurgery to the pituitary gland in Cushing’s disease. Acta Endocrinol. (Copenh.) 112: 310, 1986.
Miller J.W., Crapo L. The medical treatment of Cushing’s syndrome. Endocr. Rev. 14: 443, 1993.
Maraka G.B., Stark E. Effect of γ-aminobutiric acid (GABA) and GABA antagonist drugs on ACTH release. Neuroendocrinology 16: 178, 1974.
Jones M.T., Hillhouse E.W. Neurotransmitter regulation of corticotropin releasing factor in vitro. Ann. N. Y. Acad. Sci. 297: 536, 1977.
Kritzler R.K., Vining E.P.G., Plotnick L.P. Sodium valproate and corticotropin suppression in the child treated for seizures. J. Pediatr. 102: 142, 1983.
Cavagnini F., Invitti C., Polli E.E. Sodium valproate in Cushing’s disease (letter). Lancet 2: 162, 1984.
Koppeschaar H.P.F., Croughs R.J.M., Van’t Verlaat J.W., Hendricks M.J., Arts C.J.M., Thijssen J.H.H., Schwarz F. Successful treatment with sodium valproate of a patient with Cushing’s disease and gross enlargement of the pituitary. Acta Endocrinol. (Copenh.) 107: 471, 1984.
Allolio B., Winkelmann W., Kaulen D., Hipp F.X., Mies R. Valproate in Cushing’s syndrome (letter). Lancet 1: 171, 1982.
Ambrosi B., Bochicchio D., Riva E., Faglia G. Effects of sodium valproate administration on plasma ACTH levels in patients with ACTH hypersecretion. J. Endocrinol. Invest. 6: 305, 1983.
Loli P., Berselli M.E., Frascalani F., Muratori F., Tagliaferri M. Lack of ACTH lowering effect of sodium valproate in patients with ACTH hypersecretion. J. Endocrinol. Invest. 7: 93, 1984.
Colao A., Merola B., Tripodi F.S., Di Samo A., Esposito V., Marzullo P., La Tessa G., Spaziante R., Lombardi G. Simultaneous and bilateral inferior petrosal sinus sampling for the diagnosis of Cushing’s disease: comparison of multihormonal assay, baseline multiple sampling and ACTH-releasing hormone test. Horm. Res. 40: 209, 1993.
Koppeschaar H.P.F., Crough R.J.M., Thijssen J.H.H., Schwarz F. Sodium valproate and heterogeneity of pituitary dependent Cushing’s syndrome (letter). Lancet 1: 1253, 1982.
Koppeschaar H.P.F., Croughs R.J.M., Thijssen J.H.H., Schwarz F. Sodium valproate and cyproheptadine may independently induce a remission in the same patients with Cushing’s disease. Acta Endocrinol. (Copenh.) 104: 160, 1983.
Glaser B., Kahana L., Elias V., Sheinfeld M. Sodium valproate and metyrapone for pituitary-dependent Cushing’s disease (letter). Lancet 2: 640, 1984.
Koppeschaar H.P.F., Croughs R.J.M., Thijssen J.H.H., Schwarz F. Response to neurotransmitters modulating drugs in patients with Cushing’s disease. Clin. Endocrinol. (Oxf.) 25: 661, 1986.
Beckers A., Stevenert A., Pirens G., Flandroy P., Sulon J., Hennen G. Cyclical Cushing’s disease and its successful control under sodium valproate. J. Endocrinol. Invest. 13: 923, 1990.
Kennedy A.L., Montgomery D.A.D. Bromocriptine for Cushing’s disease, (letter) Lancet 1: 1253, 1977.
Boscaro M., Benato M., Mantero F. Effect of bromocriptine in pituitary dependent Cushing’ s syndrome. Clin. Endocrinol. (Oxf.) 19: 485, 1983.
Merola B., Colao A., Rossi R., Spaziante R., Manco A., Lombardi G. Bilateral and simultaneous inferior petrosal sinus sampling in the early diagnosis of an ACTH-producing pituitary macroadenoma and its detection by magnetic resonance one year later. Horm. Res. 37: 64, 1992.
Angeli A., Fraira R. Ketoconazole therapy in Cushing’s disease (letter). Lancet 1: 821, 1985.
Sonino N., Boscaro M., Merola G., Mantero F. Prolonged treatment of Cushing’s disease by ketoconazole. J. Clin. Endocrinol. Metab. 61: 718, 1985.
Terzolo M., Panarelli M., Piovesan A., Torta M., Paccotti P., Angeli A. Ketoconazole treatment in Cushing’s disease. Effect on the circadian profile of plasma ACTH and cortisol. J. Endocrinol. Invest. 11: 717, 1988.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Colao, A., Pivonello, R., Tripodi, F.S. et al. Failure of long-term therapy with sodium valproate in Cushing’s disease. J Endocrinol Invest 20, 387–392 (1997). https://doi.org/10.1007/BF03347989
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03347989